Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck), indicated for adults in combination with other antiemetic agents, for the prevention of:
Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Fosaprepitant for Injection, 150 mg Single-Dose Vial, (RLD: Emend) had annual sales of approximately USD 136 million in the U.S. (IQVIA MAT July 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
